Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion
March 20, 2017 - 9:30am
Global Blood Therapeutics Inc (NASDAQ: GBT) is in the process of developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease and to improve blood oxygenation characteristics and quality of life for idiopathic pulmonary fibrosis.
The release of Phase 2a GBT440 testing in IPF, expected sometime in 2017, would be “the most material catalyst unless GBT is acquired,” Wedbush’s Liana Moussatos said in a report. She added that the recent share gains due to acquisition speculation are “too low.”
Moussatos assumed coverage of Global Blood Therapeutics ...Full story available on Benzinga.com
Continue reading this article »